Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (154)	9/17/2007 2:49:54 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 210

Asleep at the wheel, I hadn't noticed they'd selected a hedgehog candidate, IPI-926. And the next oral Hsp90 inhibitor is IPI-493. Both are in "IND enabling studies". investor.ipi.com Another thing I hadn't noticed was the way of accounting "Deferred Long Term Liability Charges 57,917" finance.yahoo.com I've no idea why they do it that way, I guess I'll have to read a quarterly report and consult a coworker who is taking accounting classes. It seems wrong that INFI only has "Net Tangible Assets $57,821" Is this some way of accounting for burn ahead of time? Thanks!